GlassScriptPhysician profile
Oksana Better
NPI 1558841668
$2,945.62
in general payments reported to CMS, 2019-2025
20 companies · $667 in 2025
The $667 reported for 2025 was more than what 78% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,803 · 2022: $107 · 2023: $283 · 2024: $84.21 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $598 · Food and Beverage: $337 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $598.20 |
| Food and Beverage | $336.61 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $633.28 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $480.39 | 2021-2024 | Enhertu |
| Amgen INC. | $433.69 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $220.19 | 2021-2023 | Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $190.73 | 2021 | |
| Tactile Systems Technology INC | $178.89 | 2021-2024 | Flexitouch Plus, Entre Plus |
| Exelixis INC. | $129.10 | 2021 | |
| Servier Pharmaceuticals LLC | $124.99 | 2021 | |
| Abbvie INC. | $101.84 | 2023 | |
| Astellas Pharma US INC | $99.95 | 2021 | |
| Seagen INC. | $98.28 | 2021 | |
| Celgene Corporation | $90.35 | 2021 | |
| Pfizer INC. | $34.06 | 2025 | |
| Daiichi Sankyo INC. | $24.11 | 2023 | Enhertu |
| Janssen Biotech, INC. | $23.33 | 2024 | Rybrevant |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $21.68 | 2023 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $19.78 | 2023 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $15.85 | 2023 | Tazverik |
| Incyte Corporation | $13.36 | 2024 | Jakafi |
| Lilly USA, LLC | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oksana Better listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.